Navigation

NICE responds to judicial review outcome

Commenting on today’s ruling, NICE Chief Executive, Andrew Dillon said: “The legal challenge to our recommendation that drugs for Alzheimer’s disease should only be prescribed to those in the moderate stage of the disease has failed.  We were challenged on six grounds, and the court found in our favour on five of them.  This ruling strengthens NICE by endorsing our approach to evaluating drugs."

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.